To the Editors: In developing countries, penicillin and chloramphenicol remain widely used to treat meningitis, and few data are available to assess the impact of antibiotic resistance on the outcome of this therapy. In the early 1990s it was shown that mortality and sequelae were increased when children treated with penicillin and chloramphenicol had pneumococcal meningitis caused by intermediately penicillin-resistant strains.1 Poor outcome was consistent with relatively limited penetration of penicillin into the cerebrospinal fluid and lack of inhibition of chloramphenicol on pneumococci at achievable CSF concentrations.1 We have recently analyzed the outcome of children with pneumococcal meningitis treated with penicillin and chloramphenicol (benzylpenicillin 200 000 IU/kg per 24 hours and chloramphenicol 100 mg/kg per 24 hours every 6 hours) in a randomized trial of dexamethazone therapy in Malawi.2 Penicillin and chloramphenicol susceptibility were assessed by disk diffusion. Although the chloramphenicol disk test discriminates between chloramphenicol intermediate and resistant strains, the oxacillin disk can only identify strains as penicillin–nonsusceptible. Nonetheless, it is likely that most strains found to be nonsusceptible in Blantyre by the oxacillin disk test, are intermediately resistant, as in a previous study from Blantyre, all of 8 meningeal, 1 empyema, and 21 carriage isolates nonsusceptible by this disk test were intermediately resistant,3 as were 95% of 146 penicillin–nonsusceptible strains from rural Malawian children.4 Of 229 pneumococcal meningitis isolates available for susceptibility testing, 39 (17%) were nonsusceptible to chloramphenicol (1 intermediate) and 47 nonsusceptible to penicillin (20%).2 In this study, mortality was not influenced by randomization to the dexamethazone group in the children treated with penicillin and chloramphenicol, so the analysis of mortality by resistance is for all the children regardless of their randomization. The risk of death was increased (RR: 1.55; 95% CI: 1.06–2.28; P = 0.03) in children with penicillin nonsusceptible, but chloramphenicol susceptible isolates: 22/45 (48%) versus children infected with fully susceptible strains 45/143 (31%). These data support the previous observation that penicillin plus chloramphenicol fail in the treatment of intermediately penicillin–resistant pneumococcal meningitis.1 Although statistically nonsignificant, there was also an increased death rate 16/35 (46%) associated with chloramphenicol–nonsusceptibility despite penicillin susceptibility (RR: 1.45; 95% CI: 0.94–2.24; P = 0.11). In 2 patients, the strain was nonsusceptible to both drugs; 1 died, and 1 survived with sequelae. Mortality associated with nonsusceptibility to either drug 39/82 (48%) was associated with significantly increased mortality (RR: 1.51; 95% CI: 1.08–2.11; P = 0.016). Survival with sequelae was common in all 3 groups—penicillin and chloramphenicol susceptible (29%), penicillin nonsusceptible only (24%), and chloramphenicol nonsusceptible only (26%). These data suggest that combination therapy (organism susceptible to both drugs) may be superior to monotherapy (resistance to 1 drug) for therapy for pneumococcal meningitis. We caution physicians and pediatricians against the use of penicillin plus chloramphenicol to treat pneumococcal meningitis, as the distribution of inter-mediate penicillin resistance among pneumococci is global. Keith P. Klugman, MBBCh, PhD Medical Research Council University of the Witwatersrand/National Institute for Communicable Diseases Respiratory and Meningeal Pathogens Research Unit Johannesburg, South Africa; and The Rollins School of Public Health Emory University Atlanta, GA Amanda L. Walsh, MSc Amos Phiri, MSc Malawi Liverpool Wellcome Trust Research Laboratories Blantyre, Malawi Elizabeth M. Molyneux, FRCPCH Pediatric Department College of Medicine Blantyre, Malawi